Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGEM 
Cullinan Oncology LLC (CGEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CGEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $26.22
1 Year Target Price $26.22
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.04% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 375.12M USD | Price to earnings Ratio - | 1Y Target Price 26.22 |
Price to earnings Ratio - | 1Y Target Price 26.22 | ||
Volume (30-day avg) 9 | Beta -0.07 | 52 Weeks Range 6.24 - 18.62 | Updated Date 09/16/2025 |
52 Weeks Range 6.24 - 18.62 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.42% | Return on Equity (TTM) -36.01% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 121792773 | Price to Sales(TTM) 26.88 |
Enterprise Value 121792773 | Price to Sales(TTM) 26.88 | ||
Enterprise Value to Revenue 11.55 | Enterprise Value to EBITDA -1.46 | Shares Outstanding 59074400 | Shares Floating 36054873 |
Shares Outstanding 59074400 | Shares Floating 36054873 | ||
Percent Insiders 4.54 | Percent Institutions 107.57 |
Upturn AI SWOT
Cullinan Oncology LLC
Company Overview
History and Background
Cullinan Oncology, founded in 2016, is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies. They went public in 2021. Their evolution has centered on acquiring and developing promising cancer treatments.
Core Business Areas
- Drug Development: Focuses on discovering and developing novel oncology therapies.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of their drug candidates.
- Partnerships: Collaborates with other pharmaceutical and biotechnology companies to advance their pipeline.
Leadership and Structure
The leadership team consists of experienced biotech executives. They have a functional organizational structure with dedicated teams for research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- CLN-081 (Anatumumab deruxtecan): An EGFR inhibitor being developed for NSCLC patients. It is currently in Phase 1/2 clinical trials. Market share is currently negligible as product is not yet approved. Competitors: AstraZeneca's Tagrisso, Boehringer Ingelheim's Gilotrif.
- CLN-619: A MICA/B-targeted antibody-drug conjugate (ADC) being developed for solid tumors. It is currently in Phase 1 clinical trials. Market share is currently negligible as product is not yet approved. Competitors: Other companies developing ADCs targeting similar pathways.
Market Dynamics
Industry Overview
The oncology market is large and growing, driven by an aging population and increasing cancer incidence. There's a high demand for novel and effective cancer therapies.
Positioning
Cullinan Oncology is positioned as a clinical-stage biotech company focused on developing innovative oncology therapies. They are focusing on targeted therapies and immunotherapies to treat a wide range of cancers.
Total Addressable Market (TAM)
The global oncology market is projected to reach over $500 billion by 2030. Cullinan Oncology is aiming to capture a share of this market with its pipeline of drug candidates targeting specific cancer types and pathways.
Upturn SWOT Analysis
Strengths
- Diversified pipeline of oncology therapies
- Experienced management team
- Focus on targeted therapies and immunotherapies
- Strong financial position
- Innovative approach to drug development
Weaknesses
- Limited commercialized products
- Reliance on clinical trial success
- High research and development costs
- Competition from larger pharmaceutical companies
Opportunities
- Potential for breakthrough therapies in underserved cancer markets
- Strategic partnerships and collaborations
- Expansion of pipeline through acquisitions or licensing
- Advancements in cancer diagnostics and personalized medicine
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from existing and emerging therapies
- Patent expirations
- Economic downturns
Competitors and Market Share
Key Competitors
- AZN
- MRK
- BMY
Competitive Landscape
Cullinan Oncology competes with larger pharmaceutical companies with more resources. Their competitive advantage lies in their innovative pipeline and focus on targeted therapies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by expansion of the drug development pipeline and progress in clinical trials.
Future Projections: Future growth is dependent on the successful development and commercialization of their drug candidates. Analyst projections vary depending on the perceived probability of success for their pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for their lead drug candidates and exploring strategic collaborations.
Summary
Cullinan Oncology is a clinical-stage oncology company with a promising pipeline, but it faces significant risks due to its dependence on clinical trial success. The company's strengths include its diversified pipeline and experienced management team. Potential threats include clinical trial failures and competition from larger companies. Success hinges on successful clinical trials and eventual commercialization of their drug candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cullinan Oncology Investor Relations
- Cullinan Oncology SEC Filings (10K, 10Q)
- Industry Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on available information and is not financial advice. The biotechnology industry is inherently risky, and investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cullinan Oncology LLC
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-01-08 | President, CEO & Director Mr. Nadim Ahmed | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://cullinantherapeutics.com |
Full time employees 111 | Website https://cullinantherapeutics.com | ||
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.